ReviewEBioMedicine2026
Current knowledge on the host-pathogen interactions of henipaviruses and novel platforms to enable further characterisation.
Review in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrated Risk Matrix and Borda Count Analysis on Importation Risk Assessment of Nipah Virus Infection - China, 1999-2026.China CDC weekly · 2026Article
- A risk-gate mechanistic-ecological framework for assessing emergence potential of henipa-related viruses.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Henipaviruses, particularly the species Nipah (NiV) and Hendra (HeV), are emerging viral threats with potential to cause a public health emergency of international concern due to their high virulence and absence of approved preventative and therapeutical countermeasures. Consequently, research of NiV and HeV is restricted to high-containment laboratories and relies heavily on in vitro models. Despite NiV and HeV initial characterisation >25 years ago, significant gaps remain in the knowledge of the host-pathogen interactions, which are an important research focus for design of therapeutics and supportive care modalities. This review summarises current knowledge in the host-pathogen interactions of henipaviruses and critically assesses the current and emerging in vivo and in vitro models for henipavirus research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.